Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors

Ku, G. Y., O'Reilly, E. M., Saltz, L. B., Schrag, D., Maki, R. G., Kelsen, D. P., Ilson, D. H. (May 2009) Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer Invest, 27 (4). pp. 402-6. ISSN 1532-4192 (Electronic)0735-7907 (Linking)

DOI: 10.1080/07357900802406327


PURPOSE: We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan. METHODS: Twenty-nine patients received cisplatin 25 mg/m(2) and bolus 5-FU 425 mg/m(2), along with irinotecan at 40, 50, and 65 mg/m(2) weekly for 4 out of 6 weeks. RESULTS: The maximum tolerated dose (MTD) for untreated patients was irinotecan 65 mg/m(2) while the MTD for previously treated patients was irinotecan 40 mg/m(2). Neutropenia and diarrhea were the major dose-limiting toxicities. Antitumor activity was noted in gastric, esophageal and pancreatic cancers. CONCLUSION: Because of the toxicity profile, combinations with continuous infusion 5-FU or capecitabine should be explored.

Item Type: Paper
Uncontrolled Keywords: Adult Aged Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Camptothecin/administration & dosage/analogs & derivatives Cisplatin/administration & dosage Diarrhea/chemically induced Digestive System Neoplasms/*drug therapy/pathology Disease Progression Drug Administration Schedule Esophageal Neoplasms/drug therapy Female Fluorouracil/administration & dosage Humans Infusions, Intravenous Injections, Intravenous Male Maximum Tolerated Dose Middle Aged Neutropenia/chemically induced Pancreatic Neoplasms/drug therapy Stomach Neoplasms/drug therapy Time Factors Treatment Outcome
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matt Covey
Date: May 2009
Date Deposited: 25 Oct 2016 20:41
Last Modified: 25 Oct 2016 20:41
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving